Show simple item record

dc.contributor.authorCohen, Pieter A
dc.contributor.authorTravis, John C
dc.contributor.authorKeizers, Peter H J
dc.contributor.authorDeuster, Patricia
dc.contributor.authorVenhuis, Bastiaan J
dc.date.accessioned2018-03-08T12:05:09Z
dc.date.available2018-03-08T12:05:09Z
dc.date.issued2017-11-08
dc.identifier.citationFour experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). 2017:1-6 Clin Toxicol (Phila)en
dc.identifier.issn1556-9519
dc.identifier.pmid29115866
dc.identifier.doi10.1080/15563650.2017.1398328
dc.identifier.urihttp://hdl.handle.net/10029/621559
dc.description.abstractThe United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks.
dc.language.isoenen
dc.titleFour experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA).en
dc.typeArticleen
dc.identifier.journalClin Toxicol 2018; 56(6):421-6en
html.description.abstractThe United States Food and Drug Administration banned the stimulant 1,3-dimethylamylamine (1,3-DMAA) from dietary supplements and warned consumers that the stimulant can pose cardiovascular risks ranging from high blood pressure to heart attacks.


This item appears in the following Collection(s)

Show simple item record